Samuel Kintz, PRESIDENT AND CEO at Enliven Therapeutics, Inc. (ELVN), sold 3,700 shares at $20.06 ($74K) on 2025-09-26, disclosed to the SEC on 2025-09-30.
Scheduled sale ($74k) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ELVN | SELL | 2025-09-25 | $56K | — | Filing → |
| ELVN | SELL | 2025-09-19 | $116K | — | Filing → |
| ELVN | SELL | 2025-08-21 | $30K | — | Filing → |